Structure Therapeutics (GPCR) released topline results for their oral weight loss drug aleniglipron. The Phase 2b study showed 11.3% placebo-adjusted weight loss at 36 weeks with the 120mg dose. A separate study testing a higher 240mg dose showed 15.3% weight loss. The discontinuation rate due to side effects was around 10%, mostly gastrointestinal issues like nausea. They found that starting with a lower 2.5mg dose significantly improved tolerability. The company plans to start Phase 3 trials in mid-2026 after meeting with the FDA.